Abstract
Accumulation of intracellular sorbitol due to increased aldose reductase (AR or ALR2) activity is one of the pathways implicated in the development of long-term diabetic complications. In the present study, we described the inhibition of ALR2 by ellagic acid (EA), a bioflavonoid present in many dietary sources. EA inhibited ALR2 with an IC50 of 48nM in a non-competitive manner. Further, EA is relatively more specific towards ALR2 as it did not inhibit aldehyde reductase, a closely related member of AKR family. Molecular docking studies support and substantiate these findings. Further, EA suppressed sorbitol accumulation in human erythrocytes, rat lens and rat retina under high glucose conditions. Finally, physiologic significance of EA was demonstrated in terms of delay of diabetic cataract in rats as a prototype model of diabetic complications. Together, these observations suggest that EA holds a therapeutic promise to prevent or treat complications of diabetes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
